Compounds in clinical Phase III and beyond.

Torsten Kessler, Michael Bayer, Christian Schwöppe, Rüdiger Liersch, Rolf M Mesters, Wolfgang E Berdel

Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2010;180():137-63

PMID: 20033382

View on PubMed

Abstract

Targeted therapies against cancer have become more and more important. In particular, the inhibition of tumor angiogenesis and vascular targeting have been the focus of new treatment strategies. Numerous new substances were developed as angiogenesis inhibitors and evaluated in clinical trials for safety, tolerance, and efficacy. With positive study results, some of these molecules have already been approved for clinical use. For example, this is true for the vascular endothelial growth factor neutralizing antibody bevacizumab (BEV) in metastatic colorectal cancer, nonsmall cell lung cancer, renal cancer, and breast cancer. The tyrosine kinase (TK) inhibitors sorafenib and sunitinib have been approved for metastatic renal cancer as well as for hepatocellular carcinoma, and sunitinib has also been approved for gastrointestinal stroma tumors. In this chapter we try to give an overview of the substances currently investigated in Phase III studies and beyond with regard to antiangiogenesis in cancer therapy.

Address: Department of Medicine, Hematology and Oncology, University of Münster, Albert-Schweitzer-Strasse, 33, 48129, Münster, Germany. [email protected]

DOI: 10.1007/978-3-540-78281-0_9

MeSH Terms: Angiogenesis Inhibitors, Axitinib, Benzenesulfonates, Clinical Trials, Phase III as Topic, Endostatins, Humans, Imidazoles, Indazoles, Indoles, Neoplasms, Niacinamide, Phenylurea Compounds, Pyridines, Pyrroles, Sorafenib, Sunitinib, Thalidomide, Vascular Endothelial Growth Factor A